Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 1—January 2011

Dispatch

Serotype Distribution and Drug Resistance in Streptococcus pneumoniae, Palestinian Territories

Randa Kattan, Amal Abu Rayyan, Inas Zheiman, Suzan Idkeidek, Sabri Baraghithi, Nabeel Rishmawi, Sultan Turkuman, Afaf Abu-Diab, Riyad Ghneim, Madeleine Zoughbi, Rula Dauodi, Raed Ghneim, Abed-El-Razeq Issa, Issa Siryani, Randa Al Qas, Rawan Liddawi, Hatem Khamash, Moein Kanaan, Hiyam Marzouqa, and Musa Y. HindiyehComments to Author 
Author affiliations: Author affiliations: Caritas Baby Hospital, Bethlehem, Palestinian Territories, West Bank (R. Kattan, N. Rishmawi, S. Turkuman, A. Abu-Diab, Riyad Ghneim, M. Zoughbi, R. Dauodi, Raed Ghneim, A.-E.-R. Issa, I. Siriani, R. Al Qas, R. Lidawi, H. Marzouqa, M.Y. Hindiyeh); Bethlehem University, Bethlehem (A. Abu Rayan, M. Kanaan, M.Y. Hindiyeh); Maqassed Islamic Hospital, East Jerusalem, Palestinian Territories (I. Zheiman, S. Idkeidk, S. Barghithi, H. Khamash)

Main Article

Table A1

Distribution of Streptococcus pneumoniae serotypes and antimicrobial susceptibility patterns, Palestinian Territories, West Bank*

Serotype No. (%) isolates Penicillin, %
Cefotaxime, %
Co-trimoxazole, %
Erythromycin, %
Ofloxacin, %
Vancomycin, %
S I R S I R S I R S I R S I R S I R
6A/B 17 (14.2) 100 0 0 100 0 0 52.9 11.8 35.3 47.1 5.9 47.1 100 0 0 100 0 0
14 16 (13.3) 87.5 13.5 0 100 0 0 18.8 6.2 75 25 0 75 87.5 12.5 0 100 0 0
1 14 (11.7) 100 0 0 100 0 0 7.14 35.7 57.1 92.9 7.1 0 100 0 0 100 0 0
9V 11 (9.2) 100 0 0 100 0 0 27.3 18.2 54.6 90.9 0 9.1 100 0 0 100 0 0
5 9 (7.5) 100 0 0 100 0 0 11.1 66.7 22.2 88.9 0 11.1 100 0 0 100 0 0
19F 8 (6.7) 100 0 0 100 0 0 37.5 12.5 50 62.5 0 37.5 100 0 0 100 0 0
4 6 (5.0) 100 0 0 100 0 0 83.3 0 16.7 66.7 16.7 16.7 100 0 0 100 0 0
19A 5 (4.2) 100 0 0 100 0 0 40 20 40 60 20 20 100 0 0 100 0 0
Sg18 5 (4.2) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
3 4 (3.3) 100 0 0 100 0 0 50 0 50 25 25 50 100 0 0 100 0 0
7F 4 (3.3) 100 0 0 100 0 0 0 0 100 50 0 50 100 0 0 100 0 0
8 3 (2.5) 100 0 0 100 0 0 0 66.7 33.3 100 0 0 100 0 0 100 0 0
23F 3 (2.5) 100 0 0 100 0 0 0 0 100 100 0 0 100 0 0 100 0 0
35B 3 (2.5) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
12F 2 (1.7) 100 0 0 100 0 0 50 50 0 100 0 0 100 0 0 100 0 0
16F 2 (1.7) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
33F 2 (1.7) 100 0 0 100 0 0 0 100 100 50 0 50 100 0 0 100 0 0
8 1 (0.8) 100 0 0 100 0 0 100 0 0 0 0 100 100 0 0 100 0 0
17F 1 (0.8) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
38F 1 (0.8) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
NT
3 (2.5)
100
0
0

100
0
0

100
0
0

100
0
0

100
0
0

100
0
0
Total
120
98.3
1.7
0

100
0
0

38.3
17.5
44.2

68.3
5
26.7

98.3
1.7
0

100
0
0
*S, susceptible; I, intermediate; R, resistant; NT, not serotyped. Boldface indicates pneumococcal conjugate valent 13 vaccine serotypes. Susceptibility testing and interpretation guidelines: penicillin MIC by Etest (S<2, I: 4, R>8 μg/mL); cefotaxime MIC by Etest (S<1, I 2, R>4 μg/mL); co-trimoxazole disk diffusion (S>19, I 16–18, R<15 mm); erythromycin disk diffusion (S>21, I 16–20, R<15 mm); ofloxacin disk diffusion (S>16, I 13–15, R<12 mm); vancomycin disk diffusion (>17 mm).

Main Article

TOP